Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer

[1]  D. Arthur.  Accelerated partial breast irradiation with interstitial brachytherapy as second conservative treatment for ipsilateral breast tumour recurrence: Multicentric study of the GEC-ESTRO Breast Cancer Working Group , 2014 .

[2]  E. Bastiaannet,et al.  Age and the effect of physical activity on breast cancer survival: A systematic review. , 2013, Cancer treatment reviews.

[3]  L. Fallowfield,et al.  Adjuvant chemotherapy in elderly women with breast cancer: patients' perspectives on information giving and decision making , 2013, Psycho-oncology.

[4]  Richard Sullivan,et al.  Economic burden of cancer across the European Union: a population-based cost analysis. , 2013, The Lancet. Oncology.

[5]  S. Sleijfer,et al.  Denosumab in breast cancer treatment. , 2013, European journal of pharmacology.

[6]  M. Glukhova,et al.  How integrins control breast biology☆ , 2013, Current opinion in cell biology.

[7]  M. Smalley,et al.  Breast cancer stem cells: obstacles to therapy. , 2013, Cancer letters.

[8]  G. Kovacs,et al.  Accelerated partial breast irradiation with interstitial brachytherapy as second conservative treatment for ipsilateral breast tumour recurrence: multicentric study of the GEC-ESTRO Breast Cancer Working Group. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[9]  M. Piccart,et al.  Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  Chad A Shaw,et al.  A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. , 2013, Cancer research.

[11]  L. Murphy,et al.  Expression of both estrogen receptor-beta 1 (ER-β1) and its co-regulator steroid receptor RNA activator protein (SRAP) are predictive for benefit from tamoxifen therapy in patients with estrogen receptor-alpha (ER-α)-negative early breast cancer (EBC). , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  W. Willett,et al.  Breast cancer risk prediction with heterogeneous risk profiles according to breast cancer tumor markers. , 2013, American journal of epidemiology.

[13]  I. Fentiman,et al.  Inflammation and breast cancer , 2013 .

[14]  S. Duffy,et al.  Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial. , 2013, European journal of cancer.

[15]  J. Yarnold,et al.  Homologous recombination mediates cellular resistance and fraction size sensitivity to radiation therapy. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[16]  M. Espié,et al.  6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. , 2013, The Lancet. Oncology.

[17]  F. Lalloo,et al.  Is multiple SNP testing in BRCA2 and BRCA1 female carriers ready for use in clinical practice? Results from a large Genetic Centre in the UK , 2013, Clinical genetics.

[18]  Jorge S. Reis-Filho,et al.  Circulating tumour cells and cell-free DNA as tools for managing breast cancer , 2013, Nature Reviews Clinical Oncology.

[19]  Robert A. Weinberg,et al.  Poised Chromatin at the ZEB1 Promoter Enables Breast Cancer Cell Plasticity and Enhances Tumorigenicity , 2013, Cell.

[20]  G. Lyratzopoulos,et al.  Variation in reported experience of involvement in cancer treatment decision making: evidence from the National Cancer Patient Experience Survey , 2013, British Journal of Cancer.

[21]  R. Mansel,et al.  Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer patients: Final analysis of the EORTC AMAROS trial (10981/22023). , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  H. Putter,et al.  Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysis. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  G. Giles,et al.  Using SNP genotypes to improve the discrimination of a simple breast cancer risk prediction model , 2013, Breast Cancer Research and Treatment.

[24]  Carlos Caldas,et al.  Genetic heterogeneity in breast cancer: the road to personalized medicine? , 2013, BMC Medicine.

[25]  A. Edwards,et al.  Psychological interventions for women with metastatic breast cancer. , 2013, The Cochrane database of systematic reviews.

[26]  S. Lelièvre,et al.  Polarity proteins as regulators of cell junction complexes: implications for breast cancer. , 2013, Pharmacology & therapeutics.

[27]  P. Coleman,et al.  Living into old age with the consequences of breast cancer. , 2013, European journal of oncology nursing : the official journal of European Oncology Nursing Society.

[28]  Tanja Fehm,et al.  Metabolomics approach for predicting response to neoadjuvant chemotherapy for breast cancer , 2013, Molecular oncology.

[29]  Tim Holland-Letz,et al.  Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay , 2013, Nature Biotechnology.

[30]  A. LaCroix,et al.  Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data , 2013, The Lancet.

[31]  O. Olopade,et al.  The role of tumor-associated macrophages in breast cancer , 2015 .

[32]  George W. Sledge,et al.  A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast , 2013, Journal of the National Cancer Institute.

[33]  I. Tomlinson,et al.  What Can Be Learnt about Disease Progression in Breast Cancer Dormancy from Relapse Data? , 2013, PloS one.

[34]  N. Rosenfeld,et al.  Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA , 2013, Nature.

[35]  Sung-Bae Kim,et al.  Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. , 2013, The Lancet. Oncology.

[36]  F. Couch,et al.  BRCA1/2 sequence variants of uncertain significance: a primer for providers to assist in discussions and in medical management. , 2013, The oncologist.

[37]  L. Fallowfield,et al.  Adjuvant chemotherapy in elderly women with breast cancer (AChEW): an observational study identifying MDT perceptions and barriers to decision making. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  C. Zahnow,et al.  The future of epigenetic therapy in solid tumours—lessons from the past , 2013, Nature Reviews Clinical Oncology.

[39]  M. Smyth,et al.  The pre-metastatic niche: finding common ground , 2013, Cancer and Metastasis Reviews.

[40]  R. Kerbel,et al.  A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs. , 2013, Cancer research.

[41]  G. Wahl,et al.  Stem Cells and the Developing Mammary Gland , 2013, Journal of Mammary Gland Biology and Neoplasia.

[42]  A. Buzdar,et al.  Using Multiple Targeted Therapies in Oncology: Considerations for Use, and Progress to Date in Breast Cancer , 2013, Drugs.

[43]  P. Osten,et al.  Molecular hierarchy of mammary differentiation yields refined markers of mammary stem cells , 2013, Proceedings of the National Academy of Sciences.

[44]  J. Benítez,et al.  The complex genetic landscape of familial breast cancer , 2013, Human Genetics.

[45]  A. Harris,et al.  New strategies for targeting the hypoxic tumour microenvironment in breast cancer. , 2013, Cancer treatment reviews.

[46]  M. H. Chui.  Insights into cancer metastasis from a clinicopathologic perspective: Epithelial‐Mesenchymal Transition is not a necessary step , 2013, International journal of cancer.

[47]  John S Witte,et al.  Turning of COGS moves forward findings for hormonally mediated cancers , 2013, Nature Genetics.

[48]  Jaana M. Hartikainen,et al.  Large-scale genotyping identifies 41 new loci associated with breast cancer risk , 2013, Nature Genetics.

[49]  M. Piccart,et al.  Emerging targeted agents in metastatic breast cancer , 2013, Nature Reviews Clinical Oncology.

[50]  D. Mackinnon,et al.  Mechanisms in psychosocial interventions for adults living with cancer: opportunity for integration of theory, research, and practice. , 2013, Journal of consulting and clinical psychology.

[51]  P. Donnan,et al.  Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality , 2013, British Journal of Cancer.

[52]  M Hummel,et al.  Predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance , 2013, Cancer Gene Therapy.

[53]  Ming-Feng Hou,et al.  Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial , 2013, The Lancet.

[54]  Carlos Caldas,et al.  A new genome‐driven integrated classification of breast cancer and its implications , 2013, The EMBO journal.

[55]  Stefan Michiels,et al.  Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  P. Neven,et al.  Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[57]  Graham Ball,et al.  Targeting XRCC1 deficiency in breast cancer for personalized therapy. , 2013, Cancer research.

[58]  Samir J. Courdy,et al.  Patient‐Derived Models of Human Breast Cancer: Protocols for In Vitro and In Vivo Applications in Tumor Biology and Translational Medicine , 2013, Current protocols in pharmacology.

[59]  R. Weichselbaum,et al.  New Paradigms and Future Challenges in Radiation Oncology: An Update of Biological Targets and Technology , 2013, Science Translational Medicine.

[60]  F. Nedel,et al.  Tumor angiogenesis and lymphangiogenesis: tumor/endothelial crosstalk and cellular/microenvironmental signaling mechanisms. , 2013, Life sciences.

[61]  W. Willett,et al.  Fruit and vegetable intake and risk of breast cancer by hormone receptor status. , 2013, Journal of the National Cancer Institute.

[62]  M. Piccart-Gebhart,et al.  HERA TRIAL: 2 Years versus 1 Year of Trastuzumab after Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up , 2013 .

[63]  H. Azim,et al.  Targeting RANKL in breast cancer: bone metastasis and beyond , 2013, Expert review of anticancer therapy.

[64]  M. Reed,et al.  Current controversies in breast cancer surgery. , 2013, Clinical oncology (Royal College of Radiologists (Great Britain)).

[65]  Sridhar Ramaswamy,et al.  Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition , 2013, Science.

[66]  J. Yarnold,et al.  Breast radiotherapy: less is more? , 2013, Clinical oncology (Royal College of Radiologists (Great Britain)).

[67]  D. Allred,et al.  Loss of Par3 promotes breast cancer metastasis by compromising cell–cell cohesion , 2012, Nature Cell Biology.

[68]  Fan Zhang,et al.  Breast cancer subtyping from plasma proteins , 2013, BMC Medical Genomics.

[69]  R. Steele,et al.  Promoting Changes in Diet and Physical Activity in Breast and Colorectal Cancer Screening Settings: An Unexplored Opportunity for Endorsing Healthy Behaviors , 2013, Cancer Prevention Research.

[70]  Jian Luo,et al.  Inhibition of breast cancer metastases by a novel inhibitor of TGFβ receptor 1. , 2013, Journal of the National Cancer Institute.

[71]  M. Mimeault,et al.  Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells , 2013, Journal of cellular and molecular medicine.

[72]  C. Streuli,et al.  An integrin-ILK-microtubule network orients cell polarity and lumen formation in glandular epithelium , 2012, Nature Cell Biology.

[73]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[74]  R. Reisfeld.  The tumor microenvironment: a target for combination therapy of breast cancer. , 2013, Critical reviews in oncogenesis.

[75]  Steven A. Roberts,et al.  Mutational heterogeneity in cancer and the search for new cancer-associated genes , 2013 .

[76]  Nardin Samuel,et al.  Translating genomics to the clinic: implications of cancer heterogeneity. , 2013, Clinical chemistry.

[77]  J. Barrett,et al.  Evidence-based laboratory medicine in oncology drug development: from biomarkers to diagnostics. , 2013, Clinical chemistry.

[78]  Mark D. Aupperlee,et al.  Amphiregulin mediates progesterone-induced mammary ductal development during puberty , 2013, Breast Cancer Research.

[79]  Zongguang Zhou,et al.  A tumor hypoxic niche protects human colon cancer stem cells from chemotherapy , 2013, Journal of Cancer Research and Clinical Oncology.

[80]  Carsten Denkert,et al.  Molecular Pathways Molecular Pathways : Involvement of ImmunePathways in the Therapeutic Response and Outcome in Breast Cancer , 2012 .

[81]  M. Dowsett,et al.  Abstract S5-2: HERA TRIAL: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up , 2012 .

[82]  M. Shoichet,et al.  Blood vessel hyperpermeability and pathophysiology in human tumour xenograft models of breast cancer: a comparison of ectopic and orthotopic tumours , 2012, BMC Cancer.

[83]  T. Khoury.  Delay to Formalin Fixation Alters Morphology and Immunohistochemistry for Breast Carcinoma , 2012, Applied immunohistochemistry & molecular morphology : AIMM.

[84]  M. Gnant.  Overcoming endocrine resistance in breast cancer: importance of mTOR inhibition , 2012, Expert review of anticancer therapy.

[85]  S. Demaria,et al.  Radiation therapy to convert the tumor into an in situ vaccine. , 2012, International journal of radiation oncology, biology, physics.

[86]  Benjamin D. Smith.  Using chemotherapy response to personalize choices regarding locoregional therapy: a new era in breast cancer treatment? , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  Anna M Wu,et al.  Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[88]  C. Wilson,et al.  Seed, soil and secreted hormones: potential interactions of breast cancer cells with their endocrine/paracrine microenvironment and implications for treatment with bisphosphonates. , 2012, Cancer treatment reviews.

[89]  P. Hoskin,et al.  Implementation of stereotactic ablative radiotherapy (stereotactic body radiotherapy). , 2012, Clinical oncology (Royal College of Radiologists (Great Britain)).

[90]  H. Clevers,et al.  Developmental stage‐specific contribution of LGR5+ cells to basal and luminal epithelial lineages in the postnatal mammary gland , 2012, The Journal of pathology.

[91]  L. Forbat,et al.  Relational mechanisms and psychological outcomes in couples affected by breast cancer: a systematic narrative analysis of the literature , 2012, BMJ Supportive & Palliative Care.

[92]  N. Aaronson,et al.  Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatment-induced menopausal symptoms in patients with breast cancer: results of a randomized, controlled, multicenter trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  R. Weinberg,et al.  Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. , 2012, Seminars in cancer biology.

[94]  A. Thompson,et al.  Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies. , 2012, Cancer treatment reviews.

[95]  R. Kerbel.  Strategies for Improving the Clinical Benefit of Antiangiogenic Drug Based Therapies for Breast Cancer , 2012, Journal of Mammary Gland Biology and Neoplasia.

[96]  A. Shad,et al.  Use of reprogrammed cells to identify therapy for respiratory papillomatosis. , 2012, The New England journal of medicine.

[97]  K. Campbell,et al.  Review of exercise studies in breast cancer survivors: attention to principles of exercise training , 2012, British Journal of Sports Medicine.

[98]  V. Valero,et al.  Epithelial–Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer , 2012, Molecular Cancer Therapeutics.

[99]  R. Nusse,et al.  Developmental stage and time dictate the fate of Wnt/β-catenin-responsive stem cells in the mammary gland. , 2012, Cell stem cell.

[100]  Data production leads,et al.  An integrated encyclopedia of DNA elements in the human genome , 2012 .

[101]  R. Clarke,et al.  Stem cells in breast tumours: are they ready for the clinic? , 2012, European journal of cancer.

[102]  隆好 佐々木,et al.  ASCO Annual Meeting 2012 , 2012 .

[103]  R. Coleman.  Adjuvant bone-targeted therapy to prevent metastasis: lessons from the AZURE study , 2012, Current opinion in supportive and palliative care.

[104]  J. Lindh,et al.  Support group participation during the post-operative radiotherapy period increases levels of coping resources among women with breast cancer. , 2012, European journal of cancer care.

[105]  R. Tekmal,et al.  Transgenic mouse models of hormonal mammary carcinogenesis: Advantages and limitations , 2012, The Journal of Steroid Biochemistry and Molecular Biology.

[106]  A M Thompson,et al.  Neoadjuvant treatment of breast cancer. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[107]  Raymond K. Auerbach,et al.  An Integrated Encyclopedia of DNA Elements in the Human Genome , 2012, Nature.

[108]  P. Fasching,et al.  Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study , 2012, Breast Cancer Research.

[109]  M. Utley,et al.  Projections of cancer prevalence in the United Kingdom, 2010–2040 , 2012, British Journal of Cancer.

[110]  A. Thompson,et al.  Diabetes, metformin, and breast cancer: lilac time? , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[111]  Jean-Pierre Abastado,et al.  Immune Microenvironment in Tumor Progression: Characteristics and Challenges for Therapy , 2012, Journal of oncology.

[112]  C. Wilkinson,et al.  Anxiety, depression and quality of life after cancer diagnosis: what psychosocial variables best predict how patients adjust? , 2012, Psycho-oncology.

[113]  M. Arbushites,et al.  Exploration of serum metabolomic profiles and outcomes in women with metastatic breast cancer: A pilot study , 2012, Molecular oncology.

[114]  T. Lister,et al.  Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin's lymphoma in England and Wales: a National Cohort Study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[115]  A. Giordano,et al.  Critical choices for modeling breast cancer in transgenic mouse models , 2012, Journal of cellular physiology.

[116]  C. Friedenreich,et al.  Predictors of adherence to supervised and unsupervised exercise in the Alberta Physical Activity and Breast Cancer Prevention Trial. , 2012, Journal of physical activity & health.

[117]  Lymphatics, lymph nodes and the immune system: barriers and gateways for cancer spread , 2012, Clinical & Experimental Metastasis.

[118]  F. Shojaei,et al.  Anti-angiogenesis therapy in cancer: current challenges and future perspectives. , 2012, Cancer letters.

[119]  J. Duffy,et al.  How should we discuss genetic testing with women newly diagnosed with breast cancer? Design and implementation of a randomized controlled trial of two models of delivering education about treatment-focused genetic testing to younger women newly diagnosed with breast cancer , 2012, BMC Cancer.

[120]  N. Mutrie,et al.  Five-year follow-up of participants in a randomised controlled trial showing benefits from exercise for breast cancer survivors during adjuvant treatment. Are there lasting effects? , 2012, Journal of Cancer Survivorship.

[121]  J. Harrell,et al.  Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures , 2012, Breast Cancer Research and Treatment.

[122]  J. Baselga,et al.  Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[123]  Thomas R. Cox,et al.  The rationale for targeting the LOX family in cancer , 2012, Nature Reviews Cancer.

[124]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[125]  ENCODEConsortium,et al.  An Integrated Encyclopedia of DNA Elements in the Human Genome , 2012, Nature.

[126]  R. Stevens,et al.  Case-control study of shift-work and breast cancer risk in Danish nurses: impact of shift systems. , 2012, European journal of cancer.

[127]  L. Ritterband,et al.  Initial evaluation of an Internet intervention to improve the sleep of cancer survivors with insomnia , 2012, Psycho-oncology.

[128]  E. Perez,et al.  Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. , 2012, The Lancet. Oncology.

[129]  C. Chen,et al.  Exosome removal as a therapeutic adjuvant in cancer , 2012, Journal of Translational Medicine.

[130]  Irmtraud M. Meyer,et al.  The clonal and mutational evolution spectrum of primary triple-negative breast cancers , 2012, Nature.

[131]  A. Sivachenko,et al.  Sequence analysis of mutations and translocations across breast cancer subtypes , 2012, Nature.

[132]  L. Postovit,et al.  A Unique 3D In Vitro Cellular Invasion Assay , 2012, Journal of biomolecular screening.

[133]  P. Francis,et al.  Strategies for the discovery and development of therapies for metastatic breast cancer , 2012, Nature Reviews Drug Discovery.

[134]  P. Steeg.  Perspective: The right trials , 2012, Nature.

[135]  L. Eriksson,et al.  Mammographic density and molecular subtypes of breast cancer , 2012, British Journal of Cancer.

[136]  I. Tinhofer,et al.  Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition , 2012, BMC Cancer.

[137]  Mary Wilson,et al.  Assessing Individual Breast Cancer Risk within the U.K. National Health Service Breast Screening Program: A New Paradigm for Cancer Prevention , 2012, Cancer Prevention Research.

[138]  Soo-Chin Lee,et al.  Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer , 2012, International journal of breast cancer.

[139]  P. Goodwin,et al.  Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis , 2012, Breast Cancer Research and Treatment.

[140]  Xiaoqing Dai,et al.  Hypoxia-induced autophagy confers resistance of breast cancer cells to ionizing radiation. , 2012, Oncology research.

[141]  A. Hill,et al.  AIB1:ERα Transcriptional Activity Is Selectively Enhanced in Aromatase Inhibitor–Resistant Breast Cancer Cells , 2012, Clinical Cancer Research.

[142]  J. Manson,et al.  Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. , 2012, The Lancet. Oncology.

[143]  Michael Jones,et al.  Intragenic ATM methylation in peripheral blood DNA as a biomarker of breast cancer risk. , 2012, Cancer research.

[144]  Scarlet F. Brockmöller,et al.  Metabolomics of human breast cancer: new approaches for tumor typing and biomarker discovery , 2012, Genome Medicine.

[145]  Swathi Bisana,et al.  Mammary gland stem cells: More puzzles than explanations , 2012, Journal of Biosciences.

[146]  Andreas Wicki,et al.  Molecular Oncology: Targeted therapies in breast cancer , 2013 .

[147]  H. Dvorak,et al.  Concordant release of glycolysis proteins into the plasma preceding a diagnosis of ER+ breast cancer. , 2012, Cancer research.

[148]  Jian Jin,et al.  Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer , 2012, Cell.

[149]  O. Riou,et al.  Role of the Radiotherapy Boost on Local Control in Ductal Carcinoma In Situ , 2012, International journal of surgical oncology.

[150]  R. Datar,et al.  Progress in circulating tumor cell capture and analysis: implications for cancer management , 2012, Expert review of molecular diagnostics.

[151]  J. Haviland,et al.  Quality of life and experience of care in women with metastatic breast cancer: a cross-sectional survey. , 2012, Journal of pain and symptom management.

[152]  F. Clatot,et al.  Elevated HER2 extracellular domain level in primary breast cancer with HER2 overexpression predicts early failure of adjuvant trastuzumab. , 2012, Anticancer research.

[153]  Forrest M Kievit,et al.  Targeting of primary breast cancers and metastases in a transgenic mouse model using rationally designed multifunctional SPIONs. , 2012, ACS nano.

[154]  Paul Ellis,et al.  Dissecting the heterogeneity of triple-negative breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[155]  Maria Vinci,et al.  Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation , 2012, BMC Biology.

[156]  Nita Ahuja,et al.  Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. , 2012, Cancer cell.

[157]  Douglas Hanahan,et al.  Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment Prospects and Obstacles for Therapeutic Targeting of Function-enabling Stromal Cell Types , 2022 .

[158]  H. Gómez,et al.  A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer , 2012, Breast Cancer Research and Treatment.

[159]  P. Workman,et al.  Discovery of small molecule cancer drugs: Successes, challenges and opportunities , 2012, Molecular oncology.

[160]  Patrick Granton,et al.  Radiomics: extracting more information from medical images using advanced feature analysis. , 2012, European journal of cancer.

[161]  John C Waterton,et al.  Qualification of imaging biomarkers for oncology drug development. , 2012, European journal of cancer.

[162]  E. Grunfeld,et al.  Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial , 2012, The Lancet. Oncology.

[163]  N. Thacker,et al.  Quantifying heterogeneity in human tumours using MRI and PET. , 2012, European journal of cancer.

[164]  R. Gelber,et al.  Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial , 2012, The Lancet.

[165]  B. Coles,et al.  Cancer genetic risk assessment for individuals at risk of familial breast cancer. , 2012, The Cochrane database of systematic reviews.

[166]  M. Piccart,et al.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. , 2012, The New England journal of medicine.

[167]  R. Peto,et al.  Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. , 2012, Lancet.

[168]  D. Cutter,et al.  Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials , 2012, The Lancet.

[169]  J. Reis-Filho,et al.  Epithelial and Mesenchymal Subpopulations Within Normal Basal Breast Cell Lines Exhibit Distinct Stem Cell/Progenitor Properties , 2012, Stem cells.

[170]  Deborah Hughes,et al.  Gene-gene interactions in breast cancer susceptibility. , 2012, Human molecular genetics.

[171]  Chris Albanese,et al.  ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. , 2012, The American journal of pathology.

[172]  D B Evans,et al.  Sequential changes in gene expression profiles in breast cancers during treatment with the aromatase inhibitor, letrozole , 2010, The Pharmacogenomics Journal.

[173]  R. Chlebowski,et al.  Bisphosphonates and breast cancer prevention. , 2012, Anti-cancer agents in medicinal chemistry.

[174]  Duncan J Macfarlane,et al.  Physical activity for cancer survivors: meta-analysis of randomised controlled trials , 2012, BMJ : British Medical Journal.

[175]  Jenny C. Chang,et al.  Epithelial-mesenchymal transition, cancer stem cells and treatment resistance , 2012, Breast Cancer Research.

[176]  Sung-Bae Kim,et al.  Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. , 2012, The New England journal of medicine.

[177]  E. Watson,et al.  Personalised cancer follow-up: risk stratification, needs assessment or both? , 2012, British Journal of Cancer.

[178]  I. Ellis,et al.  Differential oestrogen receptor binding is associated with clinical outcome in breast cancer , 2011, Nature.

[179]  S. Badve,et al.  Breast-cancer stem cells-beyond semantics. , 2012, The Lancet. Oncology.

[180]  C. L. La Porta.  Thoughts about cancer stem cells in solid tumors. , 2012, World journal of stem cells.

[181]  A. Thompson,et al.  Biomarker discordance: prospective and retrospective evidence that biopsy of recurrent disease is of clinical utility. , 2012, Cancer biomarkers : section A of Disease markers.

[182]  B. A. Carter,et al.  Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group , 2012 .

[183]  J. Dixon,et al.  ABC of breast diseases , 2012 .

[184]  K. Nackaerts,et al.  Bisphosphonates: Prevention of Bone Metastases in Lung Cancer , 2012 .

[185]  R. Molina,et al.  Circulating levels of HER-2/neu oncoprotein in breast cancer , 2012, Clinical chemistry and laboratory medicine.

[186]  Giulia Bianchi,et al.  Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. , 2012, The Lancet. Oncology.

[187]  A. Dopazo,et al.  Identification of disease-relevant genes for molecularly-targeted drug discovery. , 2012, Current cancer drug targets.

[188]  K. Campbell,et al.  Review of exercise studies in breast cancer survivors: attention to principles of exercise training. , 2012, British journal of sports medicine.

[189]  M. Gnant,et al.  Bisphosphonates: prevention of bone metastases in breast cancer. , 2012, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[190]  B. Park,et al.  Androgen receptor as a targeted therapy for breast cancer. , 2012, American journal of cancer research.

[191]  R. Gelber,et al.  Lapatinib with trastuzumab for HER 2-positive early breast cancer ( NeoALTTO ) : a randomised , open-label , multicentre , phase 3 trial , 2012 .

[192]  L. Norton,et al.  Self-seeding in cancer. , 2012, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[193]  F. Berrino,et al.  Lifestyle and Breast Cancer Recurrences: The DIANA-5 Trial , 2012, Tumori.

[194]  R. Gillies,et al.  Targeting the metabolic microenvironment of tumors. , 2012, Advances in pharmacology.

[195]  T. Iwase,et al.  Eradication of breast cancer cells in patients with distant metastasis: the finishing touches? , 2012, Breast Cancer.

[196]  P. Butow,et al.  Looking different, feeling different: women’s reactions to risk-reducing breast and ovarian surgery , 2012, Familial Cancer.

[197]  M. Bissell,et al.  The tumor microenvironment modulates tamoxifen resistance in breast cancer: a role for soluble stromal factors and fibronectin through β1 integrin , 2012, Breast Cancer Research and Treatment.

[198]  G. Barrière,et al.  Mesenchymal and stemness circulating tumor cells in early breast cancer diagnosis , 2012, BMC Cancer.

[199]  J. Edwards,et al.  Shorter disease-specific survival of ER-positive breast cancer patients with high cytoplasmic Src kinase expression after tamoxifen treatment , 2012, Journal of Cancer Research and Clinical Oncology.

[200]  Jianjun Liu,et al.  Breast cancer risk prediction and individualised screening based on common genetic variation and breast density measurement , 2011, Breast Cancer Research.

[201]  Tanja Fehm,et al.  Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells , 2012, Breast Cancer Research.

[202]  V. Anisimov,et al.  Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice , 2011, Cell cycle.

[203]  Steven A. Carr,et al.  The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices , 2011, Molecular & Cellular Proteomics.

[204]  R. Peto,et al.  The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010 , 2011, British Journal of Cancer.

[205]  D. Parkin,et al.  16. The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010 , 2011, British Journal of Cancer.

[206]  H. Harputluoglu,et al.  Breast cancer subtypes and outcomes of central nervous system metastases. , 2011, Breast.

[207]  A. Hendrix,et al.  Exosome signaling in mammary gland development and cancer. , 2011, The International journal of developmental biology.

[208]  Jack Cuzick,et al.  Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. , 2011, Journal of the National Cancer Institute.

[209]  L. Richard,et al.  How can grafted breast cancer models be optimized? , 2011, Cancer biology & therapy.

[210]  F. Sotgia,et al.  Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells , 2011, Cancer biology & therapy.

[211]  R Peto,et al.  Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials , 2011, The Lancet.

[212]  A. Rocha,et al.  Distinct stem cells contribute to mammary gland development and maintenance , 2011, Nature.

[213]  S. Brearley,et al.  Knowledge, ignorance and priorities for research in key areas of cancer survivorship: findings from a scoping review , 2011, British Journal of Cancer.

[214]  C. Foster,et al.  Recovery and self-management support following primary cancer treatment , 2011, British Journal of Cancer.

[215]  L. Pusztai,et al.  Gene expression profiling in breast cancer: classification, prognostication, and prediction , 2011, The Lancet.

[216]  H. Ford,et al.  Breast cancer epithelial-to-mesenchymal transition: examining the functional consequences of plasticity , 2011, Breast Cancer Research.

[217]  V. Longo,et al.  Intermittent supplementation with rapamycin as a dietary restriction mimetic , 2011, Aging.

[218]  M. Friedlander,et al.  A specialist breast care nurse role for women with metastatic breast cancer: enhancing supportive care. , 2011, Oncology nursing forum.

[219]  Joshua M. Stuart,et al.  Subtype and pathway specific responses to anticancer compounds in breast cancer , 2011, Proceedings of the National Academy of Sciences.

[220]  Kornelia Polyak,et al.  Heterogeneity in breast cancer. , 2011, The Journal of clinical investigation.

[221]  J. Hicks,et al.  Insight into the heterogeneity of breast cancer through next-generation sequencing. , 2011, The Journal of clinical investigation.

[222]  E. Sahai,et al.  Cell communication networks in cancer invasion. , 2011, Current opinion in cell biology.

[223]  H. Mackay,et al.  Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. , 2011, The Lancet. Oncology.

[224]  A. Borowsky.  Choosing a mouse model: experimental biology in context--the utility and limitations of mouse models of breast cancer. , 2011, Cold Spring Harbor perspectives in biology.

[225]  R Peto,et al.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials , 2011, The Lancet.

[226]  Early Breast Cancer Trialists' Collaborative Group.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials , 2011, The Lancet.

[227]  Simon Lord,et al.  Gene expression and hypoxia in breast cancer , 2011, Genome Medicine.

[228]  J. Bensing,et al.  Breast cancer genetic counselling referrals: how comparable are the findings between the UK and the Netherlands? , 2011, Journal of Community Genetics.

[229]  Valerie Speirs,et al.  Choosing the right cell line for breast cancer research , 2011, Breast Cancer Research.

[230]  E. Vogler,et al.  Dynamic interaction between breast cancer cells and osteoblastic tissue: Comparison of Two‐ and Three‐dimensional cultures , 2011, Journal of cellular physiology.

[231]  M. Bellomi,et al.  Assessment of Pulmonary Fibrosis after Radiotherapy (RT) in Breast Conserving Surgery: Comparison between Conventional External Beam RT (EBRT) and Intraoperative RT with Electrons (ELIOT) , 2011, Technology in cancer research & treatment.

[232]  R. D'Agostino.  Changing end points in breast-cancer drug approval--the Avastin story. , 2011, The New England journal of medicine.

[233]  Jonathan W. Uhr,et al.  Controversies in clinical cancer dormancy , 2011, Proceedings of the National Academy of Sciences.

[234]  J. Lenzer.  FDA committee votes to withdraw bevacizumab for breast cancer , 2011, BMJ : British Medical Journal.

[235]  T. Key.  Endogenous oestrogens and breast cancer risk in premenopausal and postmenopausal women , 2011, Steroids.

[236]  Razelle Kurzrock,et al.  Responses to liposomal Doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: biologic rationale and implications for stem-cell research in breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[237]  R. Weinberg,et al.  Phenotypic plasticity and epithelial‐mesenchymal transitions in cancer and normal stem cells? , 2011, International journal of cancer.

[238]  S. Payne,et al.  What is the evidence for the use of mindfulness‐based interventions in cancer care? A review , 2011, Psycho-oncology.

[239]  Karen A Gelmon,et al.  Exemestane for breast-cancer prevention in postmenopausal women. , 2011, The New England journal of medicine.

[240]  S. Ivy,et al.  Breast cancer growth and metastasis: interplay between cancer stem cells, embryonic signaling pathways and epithelial-to-mesenchymal transition , 2011, Breast Cancer Research.

[241]  L. Pusztai,et al.  Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial , 2011, Breast Cancer Research and Treatment.

[242]  I. Ellis,et al.  Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer , 2011, Nature Medicine.

[243]  Larry Norton,et al.  Clinical implications of cancer self-seeding , 2011, Nature Reviews Clinical Oncology.

[244]  G. Sledge,et al.  Rethinking the metastatic cascade as a therapeutic target , 2011, Nature Reviews Clinical Oncology.

[245]  S. Agelaki,et al.  Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients , 2011, Breast Cancer Research.

[246]  S. Duffy,et al.  Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study. , 2011, Journal of the National Cancer Institute.

[247]  John M S Bartlett,et al.  Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[248]  J. Manson,et al.  Sex hormone levels and risks of estrogen receptor-negative and estrogen receptor-positive breast cancers. , 2011, Journal of the National Cancer Institute.

[249]  Baljit Singh,et al.  Expression of cancer testis antigens in human BRCA-associated breast cancers: potential targets for immunoprevention? , 2011, Cancer Immunology and Immunotherapy.

[250]  S. Shousha,et al.  Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab era. , 2011, Clinical breast cancer.

[251]  I. Fidler.  The role of the organ microenvironment in brain metastasis. , 2011, Seminars in cancer biology.

[252]  D. Lyden,et al.  The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. , 2011, Seminars in cancer biology.

[253]  P. Ganz,et al.  Physical and psychosocial recovery in the year after primary treatment of breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[254]  A. Simpson,et al.  Multiple Cancer/Testis Antigens Are Preferentially Expressed in Hormone-Receptor Negative and High-Grade Breast Cancers , 2011, PloS one.

[255]  T. Ochiya,et al.  Cancer Stem Cells in Breast Cancer , 2011, Cancers.

[256]  M. Smalley,et al.  The Cell of Origin of BRCA1 Mutation-associated Breast Cancer: A Cautionary Tale of Gene Expression Profiling , 2011, Journal of Mammary Gland Biology and Neoplasia.

[257]  J. Jonkers,et al.  Studying Therapy Response and Resistance in Mouse Models for BRCA1-Deficient Breast Cancer , 2011, Journal of Mammary Gland Biology and Neoplasia.

[258]  H. Feigelson,et al.  Weight loss and postmenopausal breast cancer in a prospective cohort of overweight and obese US women , 2011, Cancer Causes & Control.

[259]  A. Giuliano,et al.  Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. , 2011, JAMA.

[260]  P. Brown,et al.  Chemoprevention of hormone receptor-negative breast cancer: new approaches needed. , 2011, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[261]  R. Kerbel,et al.  Mouse models of advanced spontaneous metastasis for experimental therapeutics , 2011, Nature Reviews Cancer.

[262]  R. Schiff,et al.  Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor–Positive Metastatic Breast Cancer: A Randomized Phase II Study , 2011, Clinical Cancer Research.

[263]  K. Struhl,et al.  Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion , 2011, Proceedings of the National Academy of Sciences.

[264]  S. Eccles.  Cancer Metastasis: Growth Regulatory Pathways Contributing to Organ Selectivity of Metastasis , 2011 .

[265]  R. Speck,et al.  Erratum to: An update of controlled physical activity trials in cancer survivors: a systematic review and meta-analysis , 2011 .

[266]  J. Yarnold,et al.  Hypofractionated whole-breast radiotherapy for women with early breast cancer: myths and realities. , 2011, International journal of radiation oncology, biology, physics.

[267]  Peter Greenwald,et al.  Biomarkers for early detection and as surrogate endpoints in cancer prevention trials: issues and opportunities. , 2011, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[268]  C. Friedenreich.  Physical activity and breast cancer: review of the epidemiologic evidence and biologic mechanisms. , 2011, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[269]  Wei Wu.  MicroRNA and Cancer , 2011, Methods in Molecular Biology.

[270]  D. Lyden,et al.  Cancer metastasis : biologic basis and therapeutics , 2011 .

[271]  L. O’Driscoll,et al.  Intracellular and extracellular microRNAs in breast cancer. , 2011, Clinical chemistry.

[272]  J. Bartlett,et al.  The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study , 2011, Breast Cancer Research and Treatment.

[273]  E. Mann,et al.  A randomised controlled trial of a cognitive behavioural intervention for women who have menopausal symptoms following breast cancer treatment (MENOS 1): Trial protocol , 2011, BMC Cancer.

[274]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[275]  M. Beckmann,et al.  The German SUCCESS C Study – The First European Lifestyle Study on Breast Cancer , 2010, Breast Care.

[276]  Mads Thomassen,et al.  Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. , 2010, Cancer research.

[277]  Alastair M Thompson,et al.  Differential contextual responses of normal human breast epithelium to ionizing radiation in a mouse xenograft model. , 2010, Cancer research.

[278]  A. Sbarbati,et al.  Mesenchymal/Stromal Gene Expression Signature Relates to Basal-Like Breast Cancers, Identifies Bone Metastasis and Predicts Resistance to Therapies , 2010, PloS one.

[279]  A. LaCroix,et al.  Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. , 2010, Journal of the National Cancer Institute.

[280]  E. Chen,et al.  Identification of a stem-like cell population by exposing metastatic breast cancer cell lines to repetitive cycles of hypoxia and reoxygenation , 2010, Breast Cancer Research.

[281]  A. Thompson,et al.  Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS) , 2010, Breast Cancer Research.

[282]  J. Capala,et al.  Molecular imaging of HER2-positive breast cancer: a step toward an individualized ‘image and treat’ strategy , 2010, Current opinion in oncology.

[283]  J. Manson,et al.  Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. , 2010, JAMA.

[284]  Matthew Freiberg,et al.  Alcohol consumption and risk of postmenopausal breast cancer by subtype: the women's health initiative observational study. , 2010, Journal of the National Cancer Institute.

[285]  M. Flister,et al.  Lymphangiogenesis and lymphatic metastasis in breast cancer. , 2010, Pathophysiology : the official journal of the International Society for Pathophysiology.

[286]  V. Speirs,et al.  Phosphorylation of estrogen receptor beta at serine 105 is associated with good prognosis in breast cancer. , 2010, The American journal of pathology.

[287]  A. Tutt,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial , 2010, The Lancet.

[288]  H. Tesch,et al.  Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial , 2010, Breast Cancer Research and Treatment.

[289]  L. Esserman,et al.  Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial , 2010, The Lancet.

[290]  Hai-Wei Yang,et al.  Human tissue-specific microenvironment: an essential requirement for mouse models of breast cancer. , 2010, Oncology reports.

[291]  J. Nevins,et al.  Mouse models of cancers: opportunities to address heterogeneity of human cancer and evaluate therapeutic strategies , 2010, Journal of Molecular Medicine.

[292]  V. Brower.  Homing in on mechanisms linking breast density to breast cancer risk. , 2010, Journal of the National Cancer Institute.

[293]  C. Croce,et al.  MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer. , 2010, Journal of the National Cancer Institute.

[294]  D. Evans,et al.  Assessing women at high risk of breast cancer: a review of risk assessment models. , 2010, Journal of the National Cancer Institute.

[295]  T. Giraldi,et al.  An Early Structured Psychoeducational Intervention in Patients With Breast Cancer: Results From a Feasibility Study , 2010, Cancer nursing.

[296]  Jack Cuzick,et al.  Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[297]  J. Addington-hall,et al.  What Facilitates or Impedes Family Communication Following Genetic Testing for Cancer Risk? A Systematic Review and Meta-Synthesis of Primary Qualitative Research , 2010, Journal of Genetic Counseling.

[298]  I. Kunkler.  Adjuvant chest wall radiotherapy for breast cancer: black, white and shades of grey. , 2010, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[299]  B. Dunn.  S5 Biomarkers for early detection and as surrogate endpoints in cancer prevention trials: issues and opportunities , 2010 .

[300]  R. Pötter,et al.  Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: recommendations of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009). , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[301]  A. Ashworth,et al.  FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. , 2010, Cancer research.

[302]  Ellen Peters,et al.  Breast Cancer Patients’ Treatment Expectations after Exposure to the Decision Aid Program Adjuvant Online: The Influence of Numeracy , 2010, Medical decision making : an international journal of the Society for Medical Decision Making.

[303]  S. Lelièvre.  Tissue Polarity-Dependent Control of Mammary Epithelial Homeostasis and Cancer Development: an Epigenetic Perspective , 2010, Journal of Mammary Gland Biology and Neoplasia.

[304]  N. Miller,et al.  Potential role of mesenchymal stem cells (MSCs) in the breast tumour microenvironment: stimulation of epithelial to mesenchymal transition (EMT) , 2010, Breast Cancer Research and Treatment.

[305]  R. Clarke,et al.  Tumor and Stem Cell Biology Cancer Research Regulation of Breast Cancer Stem Cell Activity by Signaling through the Notch 4 Receptor , 2010 .

[306]  P. Pelicci,et al.  Biological and Molecular Heterogeneity of Breast Cancers Correlates with Their Cancer Stem Cell Content , 2010, Cell.

[307]  R. Speck,et al.  An update of controlled physical activity trials in cancer survivors: a systematic review and meta-analysis , 2010, Journal of cancer survivorship : research and practice.

[308]  G. Rennert,et al.  Use of bisphosphonates and risk of postmenopausal breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[309]  B. Haffty,et al.  Long-Term Results of Hypofractionated Radiation Therapy for Breast Cancer , 2010 .

[310]  Robert B Livingston,et al.  Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. , 2010, The Lancet. Oncology.

[311]  A. Howell,et al.  Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy , 2010, Breast Cancer Research and Treatment.

[312]  Joe W. Gray,et al.  HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment , 2010, Breast Cancer Research and Treatment.

[313]  S. Hilsenbeck,et al.  Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells , 2010, Breast Cancer Research and Treatment.

[314]  Larry Norton,et al.  Tumor Self-Seeding by Circulating Cancer Cells , 2009, Cell.

[315]  D. Faratian,et al.  Gene Expression Profiles of Endocrine Resistant Breast Tumours. , 2009 .

[316]  J. Menten,et al.  Does the Stellate Ganglion Block Reduce Severe Hot Flushes and Sleep Disturbances in Breast Cancer Patients , 2009 .

[317]  D. Potter.  Faculty Opinions recommendation of Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility. , 2009 .

[318]  Alexia Iasonos,et al.  Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. , 2009, Journal of the National Cancer Institute.

[319]  W. Fourie,et al.  Physiotherapy management of axillary web syndrome following breast cancer treatment: discussing the use of soft tissue techniques. , 2009, Physiotherapy.

[320]  P. Sismondi,et al.  Conservative surgery with and without radiotherapy in elderly patients with early-stage breast cancer: a prospective randomised multicentre trial. , 2009, Breast.

[321]  J. Visvader,et al.  Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. , 2009, Genes & development.

[322]  Saeed Sadeghi,et al.  Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[323]  J. Foekens,et al.  Distinct inherited metastasis susceptibility exists for different breast cancer subtypes: a prognosis study , 2009, Breast Cancer Research.

[324]  I. Andrulis,et al.  Aberrant Methylation of RASSF1A in Plasma DNA Before Breast Cancer Diagnosis in the Breast Cancer Family Registry , 2009, Cancer Epidemiology, Biomarkers and Prevention.

[325]  Yibin Kang,et al.  From breast to the brain: unraveling the puzzle of metastasis organotropism. , 2009, Journal of molecular cell biology.

[326]  P. Meltzer,et al.  Vorinostat Inhibits Brain Metastatic Colonization in a Model of Triple-Negative Breast Cancer and Induces DNA Double-Strand Breaks , 2009, Clinical Cancer Research.

[327]  A. Giobbie-Hurder,et al.  Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. , 2009, The New England journal of medicine.

[328]  Lawrence B Marks,et al.  Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). , 2009, Journal of the American College of Surgeons.

[329]  J. Snowden,et al.  Follow-up care for cancer survivors: views of the younger adult , 2009, British Journal of Cancer.

[330]  R. Santen,et al.  Estrogen signals via an extra-nuclear pathway involving IGF-1R and EGFR in tamoxifen-sensitive and -resistant breast cancer cells , 2009, Steroids.

[331]  D Brewster,et al.  Cancer prevalence in the United Kingdom: estimates for 2008 , 2009, British Journal of Cancer.

[332]  R. Gelber,et al.  Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009 , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[333]  C. Foster,et al.  Psychosocial implications of living 5 years or more following a cancer diagnosis: a systematic review of the research evidence. , 2009, European journal of cancer care.

[334]  S. Aiyar,et al.  Mechanisms of resistance to structurally diverse antiestrogens differ under premenopausal and postmenopausal conditions: evidence from in vitro breast cancer cell models. , 2009, Endocrinology.

[335]  L. Milas,et al.  Cancer stem cells and tumor response to therapy: current problems and future prospects. , 2009, Seminars in radiation oncology.

[336]  Melanie D W Seah,et al.  Rethinking undertreatment in elderly breast cancer patients. , 2009, Asian journal of surgery.

[337]  M. J. van de Vijver,et al.  Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patients. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[338]  R. Weinberg,et al.  Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits , 2009, Nature Reviews Cancer.

[339]  Paula D. Bos,et al.  Metastasis: from dissemination to organ-specific colonization , 2009, Nature Reviews Cancer.

[340]  J. Haviland,et al.  Menopausal hot flushes after breast cancer. , 2009, European journal of cancer care.

[341]  S. Fox,et al.  The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy , 2009, British Journal of Cancer.

[342]  Trevor Murrells,et al.  Patients' supportive care needs beyond the end of cancer treatment: a prospective, longitudinal survey. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[343]  J. Dungan.  A Randomized Controlled Trial of Relaxation Training to Reduce Hot Flashes in Women with Primary Breast Cancer , 2009 .

[344]  J. Yarnold,et al.  Local relapse rates are falling after breast conserving surgery and systemic therapy for early breast cancer: can radiotherapy ever be safely withheld? , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[345]  A. Harris,et al.  Targeting tumour hypoxia in breast cancer. , 2008, European journal of cancer.

[346]  P. Borst,et al.  High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs , 2008, Proceedings of the National Academy of Sciences.

[347]  M. Katz,et al.  Arm/hand swelling and perceived functioning among breast cancer survivors 12 years post-diagnosis: CALGB 79804 , 2008, Journal of cancer survivorship : research and practice.

[348]  Takuji Iwase,et al.  Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[349]  S. Stewart,et al.  Addressing the needs of young breast cancer survivors at the 5 year milestone: can a short-term, low intensity intervention produce change? , 2008, Journal of cancer survivorship : research and practice.

[350]  A. Troxel,et al.  Prevalence and treatment patterns of physical impairments in patients with metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[351]  Wenjun Guo,et al.  The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.

[352]  F. Pépin,et al.  Stromal gene expression predicts clinical outcome in breast cancer , 2008, Nature Medicine.

[353]  Martin Wiseman,et al.  The Second World Cancer Research Fund/American Institute for Cancer Research Expert Report. Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective , 2008, Proceedings of the Nutrition Society.

[354]  J. Yarnold,et al.  The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial , 2008, The Lancet. Oncology.

[355]  M. Hendrix,et al.  Hypoxia/reoxygenation: A dynamic regulator of lysyl oxidase‐facilitated breast cancer migration , 2008, Journal of cellular biochemistry.

[356]  J R Yarnold,et al.  The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial , 2008, The Lancet.

[357]  L. Hoey,et al.  Systematic review of peer-support programs for people with cancer. , 2008, Patient education and counseling.

[358]  H. Dvorak,et al.  Vascular permeability, vascular hyperpermeability and angiogenesis , 2008, Angiogenesis.

[359]  A. Ashworth,et al.  Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. , 2008, Cancer cell.

[360]  N. Boyd,et al.  Mammographic density. Potential mechanisms of breast cancer risk associated with mammographic density: hypotheses based on epidemiological evidence , 2008, Breast Cancer Research.

[361]  A. Edwards,et al.  Psychological interventions for women with metastatic breast cancer. , 2008, The Cochrane database of systematic reviews.

[362]  A. Howell,et al.  Evaluation of the current knowledge limitations in breast cancer research: a gap analysis , 2008, Breast Cancer Research.

[363]  G. Landberg,et al.  Hypoxia and breast cancer: prognostic and therapeutic implications. , 2007, Cellular and molecular life sciences : CMLS.

[364]  P. Jacobsen,et al.  Screening for psychological distress in cancer patients: challenges and opportunities. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[365]  M. Cazzaniga,et al.  Randomized dose-ranging trial of tamoxifen at low doses in hormone replacement therapy users. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[366]  M. Hotopf,et al.  A randomized controlled trial to evaluate the effectiveness of a brief, behaviorally oriented intervention for cancer‐related fatigue , 2007, Cancer.

[367]  H. Bartelink,et al.  Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[368]  M. Karamouzis,et al.  Quality of life in metastatic breast cancer patients under chemotherapy or supportive care: a single-institution comparative study. , 2007, European journal of cancer care.

[369]  G. Bleijenberg,et al.  Cognitive behaviour therapy for fatigued cancer survivors: long-term follow-up , 2007, British Journal of Cancer.

[370]  Loki Natarajan,et al.  Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and Living (WHEL) randomized trial. , 2007, JAMA.

[371]  C. Lewis,et al.  Inflammation and breast cancer. Microenvironmental factors regulating macrophage function in breast tumours: hypoxia and angiopoietin-2 , 2007, Breast Cancer Research.

[372]  石黒 千映子.  What's going on 進行乳癌患者の、緩和を目的とした化学療法の意思決定に関する論文[Grunfeld EA, Maher EJ, Browne S, Ward P, Young T, Vivat B, Walker G, Wilson C, Potts HW, Westcombe AM, Richards MA, Ramirez AJ'Advanced breast cancer patients' perceptions of decision making for palliative chemotherapy'] , 2007 .

[373]  S. Cummings,et al.  Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. , 2007, Endocrine-related cancer.

[374]  Howard Y. Chang,et al.  Decoding global gene expression programs in liver cancer by noninvasive imaging , 2007, Nature Biotechnology.

[375]  S. Eccles,et al.  Metastasis: recent discoveries and novel treatment strategies , 2007, The Lancet.

[376]  L. Andrews,et al.  Psychological adjustment among partners of women at high risk of developing breast/ovarian cancer , 2007, Genetics in Medicine.

[377]  Genee Y. Lee,et al.  Three-dimensional culture models of normal and malignant breast epithelial cells , 2007, Nature Methods.

[378]  Y. Gunaratnam,et al.  The research priorities of patients attending UK cancer treatment centres: findings from a modified nominal group study , 2007, British Journal of Cancer.

[379]  Wolfgang Heller,et al.  Triple-negative breast cancer: therapeutic options. , 2007, The Lancet. Oncology.

[380]  P. Lønning,et al.  Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial , 2007, The Lancet.

[381]  R. Eeles,et al.  Predictive genetic testing for BRCA1/2 in a UK clinical cohort: three-year follow-up , 2007, British Journal of Cancer.

[382]  R. Krauss.  Low-Fat Dietary Pattern and Risk of Invasive Breast Cancer: The Women's Health Initiative Randomized Controlled Dietary Modification Trial , 2006, Current atherosclerosis reports.

[383]  E. Riboli,et al.  The second expert report, Food, Nutrition, Physical Activity and the Prevention of Cancer: A Global Perspective , 2007 .

[384]  Elizabeth Lobb,et al.  A randomized controlled trial of a decision aid for women considering genetic testing for breast and ovarian cancer risk , 2007, Breast Cancer Research and Treatment.

[385]  M. Cronin,et al.  Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[386]  W. Willett,et al.  Adult weight change and risk of postmenopausal breast cancer. , 2006, JAMA.

[387]  K. Holli,et al.  Intensity of diagnostic and treatment activities during the end of life of patients with advanced breast cancer , 2006, Breast Cancer Research and Treatment.

[388]  N. Kaminski,et al.  Lessons from Our Patients: Development of a Warm Autopsy Program , 2006, PLoS medicine.

[389]  Raghu Kalluri,et al.  Fibroblasts in cancer , 2006, Nature Reviews Cancer.

[390]  Michael A Richards,et al.  Advanced breast cancer patients' perceptions of decision making for palliative chemotherapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[391]  M. Feuerstein,et al.  Psychosocial Interventions for Depression, Anxiety, and Quality of Life in Cancer Survivors: Meta-Analyses , 2006, International journal of psychiatry in medicine.

[392]  J. Manson,et al.  Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. , 2006, JAMA.

[393]  J. Manson,et al.  Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. , 2006, JAMA.

[394]  T. Eberlein.  A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer , 2006 .

[395]  Naz Chaudary,et al.  Hypoxia and metastasis in breast cancer. , 2006, Breast disease.

[396]  R. Newcombe,et al.  Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer , 2006, Breast Cancer Research and Treatment.

[397]  Robert B Livingston,et al.  Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. , 2005, Journal of the National Cancer Institute.

[398]  B. Given,et al.  Taking CHARGE: A self‐management program for women following breast cancer treatment , 2005, Psycho-oncology.

[399]  Michael Gnant,et al.  Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial , 2005, The Lancet.

[400]  B. Fisher,et al.  National Surgical Adjuvant Breast and Bowel Project , 2020, Definitions.

[401]  L. Weih,et al.  Mapping the quality of life and unmet needs of urban women with metastatic breast cancer. , 2005, European journal of cancer care.

[402]  S. Eccles,et al.  Breast cancer metastasis: when, where, how? , 2005, The Lancet.

[403]  J. Cerhan,et al.  Association of Gain and Loss of Weight before and after Menopause with Risk of Postmenopausal Breast Cancer in the Iowa Women's Health Study , 2005, Cancer Epidemiology Biomarkers & Prevention.

[404]  R. Elashoff,et al.  Adjuvant dietary fat intake reduction in postmenopausal breast cancer patient management , 1991, Breast Cancer Research and Treatment.

[405]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[406]  P. Ganz,et al.  Neurocognitive Performance in Breast Cancer Survivors Exposed to Adjuvant Chemotherapy and Tamoxifen , 2004, Journal of clinical and experimental neuropsychology.

[407]  Barbara L. Smith,et al.  Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. , 2004, The New England journal of medicine.

[408]  J. Hanley,et al.  Pattern of care at the end of life: does age make a difference in what happens to women with breast cancer? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[409]  K. Ownby,et al.  The effect of seated exercise on fatigue and quality of life in women with advanced breast cancer. , 2004, Oncology nursing forum.

[410]  S. Bloch,et al.  Psychiatric Disorder in Women with Early Stage and Advanced Breast Cancer: a Comparative Analysis , 2004, The Australian and New Zealand journal of psychiatry.

[411]  M. Lacroix,et al.  Relevance of Breast Cancer Cell Lines as Models for Breast Tumours: An Update , 2004, Breast Cancer Research and Treatment.

[412]  M. Widschwendter,et al.  DNA methylation in serum of breast cancer patients: an independent prognostic marker. , 2003, Cancer research.

[413]  D. Dale.  Poor prognosis in elderly patients with cancer: the role of bias and undertreatment. , 2003, The journal of supportive oncology.

[414]  E. Passaro,et al.  Early and late cognitive changes following temporal lobe surgery for epilepsy , 2003, Neurology.

[415]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[416]  Maria Grazia Valsecchi,et al.  Psychological Aspects , 2003, International Journal of Obesity.

[417]  R. Yancik,et al.  Cancer survivors in the United States: age, health, and disability. , 2003, The journals of gerontology. Series A, Biological sciences and medical sciences.

[418]  押谷 潤,et al.  To be International , 2002 .

[419]  Lesley Fallowfield,et al.  Efficacy of a Cancer Research UK communication skills training model for oncologists: a randomised controlled trial , 2002, The Lancet.

[420]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[421]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[422]  H. Kraemer,et al.  Supportive-expressive group therapy and distress in patients with metastatic breast cancer: a randomized clinical intervention trial. , 2001, Archives of general psychiatry.

[423]  S. Enna.  Current protocols in pharmacology , 1998 .

[424]  G A Colditz,et al.  Dual effects of weight and weight gain on breast cancer risk. , 1997, JAMA.

[425]  R. Rubens,et al.  Psychiatric disorder in patients with advanced breast cancer: prevalence and associated factors. , 1993, European journal of cancer.

[426]  A. Howell,et al.  Psychiatric morbidity in patients with advanced cancer of the breast: prevalence measured by two self-rating questionnaires. , 1991, British Journal of Cancer.

[427]  H. Kraemer,et al.  EFFECT OF PSYCHOSOCIAL TREATMENT ON SURVIVAL OF PATIENTS WITH METASTATIC BREAST CANCER , 1989, The Lancet.

[428]  C. Williams.  Physical Examination of the Abdomen in Health and Disease. Part First , 1851 .